Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mercaptamine ophthalmic - Orphan Europe

Next Previous
Drug Profile

Mercaptamine ophthalmic - Orphan Europe

Alternative Names: CYSTADROPS; Cystadrops; Cysteamine chlorhydrate - Orphan Europe; Cysteamine hydrochloride - Orphan Europe; Mercaptamine hydrochloride - Orphan Europe

Latest Information Update: 20 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orphan Europe
  • Developer Orphan Europe; Recordati Rare Diseases
  • Class Anti-inflammatories; Antibacterials; Antidotes; Hepatoprotectants; Mercaptoethylamines; Mucolytics; Small molecules
  • Mechanism of Action Glutathione synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystinosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystinosis

Most Recent Events

  • 28 Sep 2022 Phase III development is still ongoing for Cystinosis (In infants) in United Kingdom, France, Germany, Italy, Belgium (Ophthalmic) (EudraCT-2018-002984-24)
  • 15 Sep 2020 Launched for Cystinosis (In adolescents, In children, In adults) in USA (Ophthalmic)
  • 25 Aug 2020 Efficacy and safety data from phase I/IIa trial in Cystinosis released by Recordati Rare Diseases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top